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Background: Breast cancer is a heterogeneous disease with various histological features and molecular markers.
These are utilized for the prediction of clinical outcome and therapeutic decision making. In addition to well
established markers such as HER2 overexpression and estrogen and progesterone receptor (ER and PR) status,
chromosomal instability is evolving as an important hallmark of cancers. The HER2/TOP2A locus is of great
importance in breast cancer. The copy number variability at this locus has been proposed to be a marker for the
degree of chromosomal instability. We therefore developed a Single Nucleotide Polymorphism (SNP) assay to
evaluate allelic imbalance at the HER2/TOP2A locus in three different entities of primary breast tumors.
Methods: Eleven SNPs were carefully selected and detected by real time PCR using DNA extracted from paired
(histologically normal and tumor) paraffin-embedded tissues. Primary breast tumors of 44 patients were included,
15 tumors with HER2 overexpression, 16 triple negative tumors, defined by the absence of HER2 overexpression
and a negative ER and PR status and 13 ER and PR positive tumors without HER2 overexpression. As controls,
histologically normal breast tissues from 10 patients with no breast tumor were included.
Results: Allelic imbalance was observed in 13/15 (87 %) HER2 positive tumors, the remaining 2 being inconclusive.
Of the 16 triple negative tumors, 12 (75 %) displayed instability, 3 (19 %) displayed no instability, and 1 was
inconclusive. Of the 13 hormone receptor positive tumors, 5 (38 %) displayed allelic imbalance, while 8 did not.
Conclusions: We conclude that the SNP assay is suitable for rapid testing of allelic (im)balance at the HER2/TOP2A
locus using paraffin-embedded tissues. Based on allelic imbalance at this locus, both triple negative and ER and PR
positive breast tumors can be subcategorized. The clinical relevance of the allelic (im)balance status at the HER2/
TOP2A locus in breast cancer is subject of future study.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/2086062232155220
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Breast cancer is a heterogeneous disease that can display
a diverse variety of biological features. Several proteins
are well known to be expressed excessively in these tu-
mors. Based on the excessive presence of such proteins,
breast cancer can be divided in several different bio-
logical entities. This breast cancer categorization is* Correspondence: r.huysmans@jbz.nl
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apy selection [1].
Well known examples of overexpressed proteins that
play a critical role in breast cancer diagnostics and
choice of therapy, are the estrogen and progesterone re-
ceptors (ER and PR). Available targeted therapies in
these breast cancer cases are e.g. Tamoxifen and aroma-
tase inhibitors [2–4].
In addition to the overexpression of ER and PR, aberra-
tions of the chromosome 17q12-q22 genomic region play
an important role in breast cancer. This locus incorporates
the HER2 gene as well as the juxtaposed TOP2A gene,tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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HER2 oncogene encodes the human epidermal growth fac-
tor receptor 2 protein, a 185 kDa transmembrane tyrosine
kinase receptor also known as erbB-2 and neu [5, 6].
Upon ligand binding the other types of HER receptors
will dimerize with HER2. Such dimerization triggers an
integrate network of HER signal transduction involving
a variety of signaling pathways [8–10]. When the HER2
oncogene is amplified, HER2 overexpression occurs
resulting in overstimulation of HER mediated signal
transduction [8]. HER2 is found to be amplified in 25–
30 % of breast cancers [11]. Patients with HER2 ampli-
fied breast tumors resulting in overexpression of HER2,
benefit from treatment with the monoclonal antibody
Trastuzamab (Herceptin). Trastuzamab is thought to
abolish the HER2 mediated signaling of the HER signal
transduction network [12, 13]. In addition, analysis of
several studies has shown an association of improved
adjuvant anthracycline (AC)-based chemotherapy re-
sponse rates in HER2 amplified breast tumors [14].
However, there is no clear AC induced HER2 inhibiting
mechanism, it is therefore suggested that TOP2A coam-
plification is the biological rationale behind these obser-
vations [15]. The TOP2A gene encodes topoisomerase II
alpha, a 170 kDa enzyme that catalyzes the topological
DNA changes needed during the multistep process of
cell division [16]. Coamplification of TOP2A occurs
along with HER2 amplification in approximately 30–
45 % of the HER2 amplified cases [15, 17, 18]. Patients
with TOP2A amplified breast tumors seem to benefit
from adjuvant AC-based chemotherapy. ACs are che-
motherapeutic agents that are known to have, among
other mechanisms of action, TOP2A inhibiting proper-
ties. TOP2A catalytic activity is inhibited by ACs via
stabilization of the intermediate complex where TOP2A
tyrosine residues are covalently linked to the 5’ phos-
phoryl ends of the cut DNA strands during the topo-
logical changes which they catalyze. Trapping the
complex in this state prevents DNA resealing and fur-
ther cell cycle progress, which ultimately induces pro-
grammed cell death [16, 19, 20]. In patients that are
treated with AC-based chemotherapy, breast tumors
with TOP2A amplification show a trend towards a better
disease free survival than tumors lacking this amplifica-
tion. In addition, TOP2A amplification is an independ-
ent predictor of a significantly higher pathological
complete response rate in these patients [18]. On the
contrary, TOP2A deletion, occurring in 15–40 % of
HER2 amplified cases, has been associated with AC re-
sistance [15, 17, 18]. Tumors lacking ER and PR overex-
pression as well as HER2 amplification are defined as
“triple negative” breast tumors. Triple negative tumors
are associated with poor clinical outcome and lack of
(currently) available targeted therapy [21, 22].The above mentioned biological characteristics are well
established biomarkers utilized to categorize breast cancer
types for diagnostic and treatment related purposes. More
recently, high resolution array based systems, targeting Sin-
gle Nucleotide Polymorphisms (SNPs) or utilizing Com-
parative Genomic Hybridization, have been employed to
subcategorize these breast tumor types and revealed dis-
tinct profiles of gene-expression or genetic alterations [23–
28]. Hormone receptor positive tumors without HER2
overexpression showed minor and less frequent chromo-
somal instability in comparison to HER2 overexpressed and
triple negative tumors that showed more extensive and
more frequent chromosomal instability [23–29]. Copy
number alterations across the genomic region incorporat-
ing the HER2/TOP2A locus have been proposed to be a
marker for the degree of chromosomal instability in breast
cancer [30, 31]. Early breast cancer patients with a tumor
containing extensive chromosomal instability, that were
treated with AC-based therapy, were shown to have a de-
creased risk of death and a trend towards a decreased risk
of relapse. Similarly treated patients with a tumor of low
chromosomal instability showed no apparent benefit [30,
31]. Determining such instability in a diagnostic setting
may therefore be of clinical relevance as an adjuvant mo-
lecular marker.
Single Nucleotide Polymorphisms (SNP) are easily de-
tected by real time PCR, a technique that is widely avail-
able in many laboratories that routinely employ molecular
diagnostics. By analyzing a panel of heterozygous SNPs,
copy number alterations and thereby allelic imbalance of
the involved locus can be determined. It therefore may
provide an accessible method to assess allelic imbalance at
the HER2/TOP2A locus.
Methods
Study population and clinical specimens
The study was carried out retrospectively with the approval
of the Board of Directors and the Scientific Advisory Board
of the Jeroen Bosch Hospital. All patient samples were ren-
dered anonymous before use in this study.
Control group
Ten histologically normal formalin-fixed paraffin-embedded
(FFPE) breast -tissues from 10 different patients (CT1-10)
with no breast tumor were included as controls (Additional
file 1: Table S1). Age of included patients was 32.8 ±
12.0 years (mean age ± 1 standard deviation (STD)).
Breast tumor patient group
Breast tumors (FFPE tissue) with known HER2 immunohis-
tochemistry (IHC) and silver in situ hybridization (SISH)
status from 44 patients were included in this study
(Additional file 2: Table S2): 15 tissues with HER2 amp-
lification (IHC 3+, patients HER2 + 1–15; aged 52.9 ±








Base (17q) SNP Minor allele frequency
CEU CHB JPT YRI
1 7214151 30187206 34,761,298 C/T 0.38 0.04 0.45 0.46
2 7503195 437172 34,976,041 A/G 0.38 0.04 0.45 0.45
3 876493 7452397 35,078,071 G/A 0.36 0.23 0.43 0.43
4 4795408 30547514 35,361,153 A/G 0.47 0.43 0.47 0.39
5 4794822 31651885 35,410,238 T/C 0.42 0.38 0.39 0.39
6 868150 471861 35,466,885 A/G 0.42 0.34 0.44 0.45
7 2015561 7479296 35,846,755 G/A 0.46 0.44 0.42 0.00
8 4890114 27932396 35,857,075 T/C 0.46 0.44 0.42 0.00
9 8065040 11876205 36,073,767 A/G 0.37 0.43 0.43 0.36
10 10491123 29903401 36,086,722 A/G 0.37 0.44 0.44 0.47
11 7502428 29885409 36,133,740 C/T 0.47 0.44 0.43 0.41
SNP-ID (rs) = reference SNP ID number. SNP-ID (hCV) = Celera SNP ID. Base
(17q) = the nucleotide position on chromosome 17(q). The HER2 gene is
positioned at base 35,097,919-35,138,441, the TOP2A gene at 35,798,321-
35,827,695 (SNP browser software Version 4.0, Applied Biosystems). SNP 1-6 were
located up- and downstream of the HER2 gene within the HER2 smallest region
of amplification [33]. The remaining 5 SNPs (7-11) were located up- and
downstream of the TOP2A gene. The particular nucleotide variation is referenced
in “SNP”-column. Minor allele frequencies are indicated for different populations:
CEU, CEPH (Centre d'Etude du Polymorphisme Humain) from Utah; CHB, Chinese
from Beijing; JPT, Japanse from Tokyo and YRI, Yoruba from Ibadan Nigeria
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tients TN1-16; aged 53.4 ± 12.9 years (mean age ± 1
STD)) and 13 ER/PR positive and HER2 non-amplified
(ERPR+) breast tumors (patients ERPR+ 1–13; aged
55.5 ± 9.3 years (mean age ± 1 STD)). To establish the
germline SNP profile, a histologically normal archival
FFPE tissue (breast tissue or lymph node tissue in case
no breast tissue was available; Additional file 2: Table S2)
from each patient was analyzed.
Tissue Processing
Tissues were fixed and processed as previously described
[32]. Three-μM-thick sections were cut from each FFPE
tissue and mounted on glass slides in sevenfold. One was
used for Hematoxylin & Eosin (HE) staining, two to four
(depending on tissue size, with a total of approximately
2 cm2) for genomic DNA extraction, one for SISH and
one for IHC. The latter two were only performed for the
tumor samples.
HER2 immunohistochemistry
To establish the HER2 expression status, IHC was per-
formed on all 44 tumor samples using the Ventana anti-
Her2/neu(4B5) (Roche Diagnostics GmbH, Mannheim,
Germany) in combination with the VENTANA system
(Roche Diagnostics GmbH) according to the manufac-
turers protocol. IHC 0 and 1+ were considered to repre-
sent normal expression, 2+ was considered borderline
with regard to expression and 3+ was considered to rep-
resent overexpression.
HER2 silver in situ hybridization
To determine the HER2 amplification status and to assess
chromosome 17 copy number status, SISH was performed
on all 44 tumor samples using the INFORM HER2 Dual
colour SISH DNA probe cocktail (Roche Diagnostics
GmbH) in combination with the VENTANA system
(Roche Diagnostics GmbH) according to the manufac-
turers protocol. Twenty nuclei were counted independ-
ently by 2 individuals. The mean from these 2 nuclei
counts was calculated. Interpretation was as follows: a ra-
tio (HER2 probe/centromere probe) of <1.8 represented
no amplification; a ratio of 1.8–2.2 was equivocal and a ra-
tio of >2.2 represented amplification.
Genomic DNA extraction from FFPE tissues
From each FFPE tissue, tumor as well as (reference) histo-
logically normal tissue, a HE-slide was made. The tumor
tissue containing HE slides were used to determine the area
with the highest tumor cell percentage (TC%). The HE
slides containing the histologically normal tissue were used
to determine the location of the highest nuclei density. Sub-
sequently, these were used as a reference for tumor and his-
tologically normal cell macrodissection, respectively. Therespective cells were scraped off the corresponding
blank slides. The scrapings were used for digestion and
subsequent EasyMAG NucliSens (BioMérieux Benelux
BV, Zaltbommel, The Netherlands) DNA extraction as
described previously [32].
SNP selection
From the TaqMan® SNP Genotyping Assays from Ap-
plied Biosystems, 11 suitable SNPs were chosen using
SNP browser software Version 4.0 (Applied Biosystems,
Table 1). SNP 1–6 were located up- and downstream of
the HER2 gene within the HER2 smallest region of amp-
lification [33]. The remaining 5 SNPs (7–11) were lo-
cated up- and downstream of the TOP2A gene. The
selected SNPs displayed an allele frequency of approxi-
mately 0.5 in Caucasian (CEU, CEPH (Centre d'Etude du
Polymorphisme Humain) from Utah), Chinese (CHB,
Chinese from Beijing), Japanese (JPT, Japanese from
Tokyo) and African (YRI, Yoruba from Ibadan Nigeria)
populations. The latter to maximize the chance for het-
erozygosity, independent of the patients’ ethnicity, for
only those SNPs are informative.
Allelic instability testing by SNP detection
For real time PCR based amplification and detection of
the selected SNPs, corresponding predesigned TaqMan®
SNP Genotyping Assays were purchased (Applied Bio-
systems, Foster City CA, USA; Table 1) containing two
primers and two MGB TaqMan probes (5’ VIC for allele
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both alleles). The SNP assays were used according to the
manufacturer's instructions. Real time PCR based SNP de-
tection was performed as previously described [32], in an
ABI Prism 7500 FAST SDS (Applied Biosystems) machine
for 1 min at 95 °C, followed by 45 cycles of 3 s at 95 °C and
30 s at 60 °C. To maximize pipetting accuracy and thereby
minimize its influence on the data generated, all initial PCR
setups were performed using the Hamilton StarLet instru-
ment (Hamilton Robotics, Bonaduz, Switzerland).
Subsequent analysis was based on the generated fluor-
escence emission intensity of the VIC and FAM reporter
dyes divided by the fluorescence emission intensity of
the passive reference ROX dye (delta Rn value). WhenFig. 1 Schematic representation of allelic instability testing by real time PC
homozygous allele 1 and homozygous allele 2 (both non-informative), hete
vs. 2 and vice versa as a conceptual example). The probe corresponding to
with a 5’ FAM reporter. Both probes contain a 3’ black hole quencher (BHQ
corresponding real time PCR component plots of above genotypes of repr
arrows indicate the approximate delta Rn of the respective VIC or FAM rep
Dotted ovals indicate hypothetical homo- and heterozygous clusters. X-axisboth alleles were present, a delta Rn VIC/FAM ratio
could be established (allele 1/allele 2). This ratio was
considered to be informative with regard to the relative
number of alleles present and therefore a reflection of
the allelic (im)balance status. Only the SNPs that were
heterozygous for a given patient were informative. A
schematic representation of this experimental scheme is
presented in Fig. 1.
For each informative SNP the VIC/FAM ratios were plot-
ted in a scatterplot. To minimize the influence of DNA
concentration on VIC/FAM ratio and therefore data inter-
pretation, the delta Rn FAM was corrected. The correction
was performed by adapting the delta Rn FAM values of the
histologically normal samples per SNP according to theR based SNP detection. a. Possible genotypes, from top to bottom:
rozygous normal and heterozygous imbalance (a 3:1 ratio of allele 1
allele 1 is labeled with a 5’ VIC reporter, the allele 2 probe is labeled
). A = Adenine, T = Thymine, G = Guanine and C = Cytosine. b. The
esentative SNP 8. X-axis: number of cycles, Y-axis: fluorescence. The
orters. c. Resulting scatterplot of SNP 8 of encountered genotypes.
: delta Rn VIC, Y-axis: delta Rn FAM
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sulted in the translocation of the trend lines of the histolog-
ically normal tissues so that they all passed through the
origin. All delta Rn FAM data of the tumor samples were
subsequently corrected accordingly.
Statistical analysis allelic instability testing
To gain insight into the distribution of delta Rn VIC/FAM
ratios (ratio allele 1/allele 2), the 25th and 75th percentiles
of the ratios generated by all histologically normal tissues
(from the control group as well as the group of breast
tumor patients) were calculated for each SNP assay using
Microsoft Office Excel 2007 (Microsoft, Redmond WA,
USA). The distance between these percentiles represents
the interquartile range (IQR), which was used to establish
cut-off values for the normal ratio distribution per SNP.
The +1.5 IQR and −1.5 IQR were taken as cut-off value
for normal ratio distribution for 10/11 SNPs (all SNPs ex-
cept SNP 3). All ratios with an IQR of <1.5 follow normal
distribution and were interpreted as genetically stable with
regard to the HER2/TOP2A locus. Ratios plotted within
1.5–3 x IQR were considered equivocal with regard to
HER2/TOP2A allelic instability status. Ratios plotted ≥3x
IQR were considered to be representative for HER2/
TOP2A allelic instability. Due to the large IQR generated
using SNP 3 (varying from 2.3 to 15.1 times as large as
found with the other SNPs), the cut-off values for that
particular SNP were defined as follows: normal = −1 to +1
IQR; equivocal = 1–2 IQR and ≥2 IQR = indicative of al-
lelic instability.
When a sample generated an equivocal result for any of
the employed SNPs, the analysis of that particular sample
was repeated in duplicate (with non-diluted DNA and
with 5-fold diluted DNA in Tris Low EDTA buffer) using
the respective SNP. When 2/3 results corresponded, the
sample was called accordingly (e.g. equivocal/equivocal/
normal was called equivocal). When results were conflict-
ing, the sample was called equivocal (e.g. equivocal/allelic
instability/normal).
Results
Two patient groups were used in this study: a control
group of 10 histologically normal tissues from patients
(CT1-10) with no breast tumors and a group of 44 breast
tumor patients with different entities of primary breast
cancer (HER2 + 1–15, TN1-16 and ERPR+ 1–13) of which
both tumor and normal tissues were available.
SNP selection
Technical validation of the selected SNP assays was per-
formed using the 10 histologically normal breast tissues
from the control group. All SNP assays had a sufficient
sensitivity, yielding cycle-threshold values of <35 (thresh-
old 0.007), a cut-off above which results are routinelyconsidered less reliable in our laboratory. In addition, little
or no cross-reaction of the SNP assays’ allele 1 correspond-
ing probes (VIC reporter) with allele 2, and of the allele 2
corresponding probes (FAM) with allele 1 was observed.
This resulted in clear clustering of homozygous allele 1,
homozygous allele 2 and heterozygous patients. The panel
of 11 SNP markers (Table 1) was therefore used to analyze
the clinical specimens (Additional file 1: Table S1 and
Additional file 2: Table S2).
SNP analysis of patient materials
To minimize the influence of DNA concentration on VIC/
FAM ratio and therefore data interpretation, a correction
on all delta Rn FAM data was performed as described in
the Materials and Methods section. Fig. 2 shows the cor-
rected scatterplot of representative SNP 8 for histologically
normal tissues from the control group and paired histologi-
cally normal and tumor samples of all patients in the breast
tumor group. Ratios of each sample pair (histologically nor-
mal and tumor tissues) were connected.
Subsequently, the delta Rn VIC/FAM ratios of all inform-
ative SNPs of the histologically normal tissues from both
groups (10 tissues from the control groups and 44 tissues
from the breast tumor group) were used to gain insight in
normal data distribution. Combining the data of the histo-
logically normal tissues from these groups was justified due
to the mutual similarity of delta Rn VIC/FAM ratio distri-
bution amongst both groups. To determine the HER2/
TOP2A allelic (im)balance, fluorescent ratios of the panel
of 11 informative SNP’s were analyzed using the cut-off
values based on the interquartile range of data distribution
amongst the histologically normal samples.
Histologically normal tissues
As expected, all informative SNP results (total of 54 SNPs
of 10 patients) of the breast tissues from the control group
fell within the normal IQR range (−1.5 to 1.5 IQR for SNP
1, 2 and 4–11 and −1 to 1 IQR for SNP 3). Overall results
are depicted in Additional file 1: Table S1, Fig. 2 repre-
sents the corrected scatterplot of representative SNP 8.
The 44 histologically normal samples of the breast tumor
patient group generated SNP results that fell within the nor-
mal IQR range and are therefore in agreement with the nor-
mal range observed in the control group. Only 1 out of the
total of 208 informative SNPs yielded an equivocal result
(patient TN2, SNP 11, triplicate analysis yielded 2 equivocal
results and 1 result was found to indicate allelic instability).
Breast tumor tissues
Results of IHC and SISH are depicted in Additional file 2:
Table S2. The SNP assays were used to investigate in more
detail the genomic composition of the HER2/TOP2A locus.





























Delta Rn VIC (T)
Scatterplot SNP 8 
Trend line
Histologically normal tissue 
of control group
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Fig. 2 Visualization of VIC/FAM ratios that were generated using representative SNP 8 after FAM correction. Scatterplot of SNP 8 analyses of histologically
normal tissues from the control group and paired histologically normal and tumor tissues from the group of breast tumor patients. Connected symbols
indicate normal and tumor tissue of a single patient. X-axis: delta Rn VIC (T = Thymine), Y-axis: corrected delta Rn FAM (C =Cytosine)
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Within the group of patients with tumors overexpressing
HER2, the SNP data of patients HER2+ 2–5 and 7–15
were consistently indicative of an instable HER2/TOP2A
locus. IHC scores were 3+, SISH ratios were 2.0–15.2
and TC% ranged from 40 to 80 %. SNP 1 in patient
HER2+ 8 generated an equivocal result. SNP results
from patient HER2+ 1 and 6 showed inconsistent results
between informative SNPs. All informative SNPs were
therefore subsequently repeated in duplicate for these
patients yielding identical results. SNP results from pa-
tient HER2+ 1 showed allelic balance of SNPs 8 and 9,
whereas results from SNPs 1 and 10 were found to indi-
cate allelic instability. IHC yielded a 3+ score, whilst the
SISH ratio was 1.1. The sample had a TC% of 30 %. SNP
results from patient HER2+ 6 were also inconsistent.
SNPs 1, 2 and 8 were indicative of allelic stability, while
results from SNPs 4, 7 and 11 showed allelic instability.
IHC, SISH ratio and TC% in this patient were 3+, 4.1
and 80 %, respectively.
Triple negative group
In the triple negative group, patients TN1-4, 6, 9, 10 and
12–16 showed SNP results consistent with instability of
the HER2/TOP2A locus. IHC scores, SISH ratios and
TC% varied from 0–2+, 0.7–1.9 and 25–90 %, respect-
ively. Several SNPs generated equivocal results in
patients TN1 (SNP 3 3x equivocal), 3 (SNP 4 3x equivo-
cal), 8 (SNP 1 2x equivocal, 1x normal and SNP 2 3x
equivocal), 10 (SNP 3 2x equivocal, 1x allelic instability)
and 13 (SNP 1 and 3 both 3x equivocal). Patients TN5,
7 and 11 revealed no signs of HER2/TOP2A allelic im-
balance, IHC scores were 0–1+, SISH yielded ratios of1.1–1.6 and the samples contained 30–95 % tumor cells.
In patient TN8, the 2 SNPs that were informative (SNPs
1 and 2) yielded equivocal results. IHC score, SISH ratio
and TC% for this patient were 1+, 0.9 and 70 %,
respectively.
Estrogen and progesterone positive group
From the ERPR+ group, patients ERPR+ 1–3, 6 and 7
yielded SNP results indicative of HER2/TOP2A locus in-
stability. IHC scores, SISH ratios and TC% varied from
0–1+, 0.5–1.1 and 30–70 %, respectively. Equivocal re-
sults were generated in patients ERPR+ 3 (SNP 3 3x
equivocal) and 7 (SNP 3 1x equivocal, 1x allelic instabil-
ity and 1x normal). The ratio of SNP 3 was found to be
equivocal (equivocal, allelic instability and normal) in
patient ERPR+ 7. The breast tumor tissues from patients
ERPR+ 4, 5 and 8–13 showed a stable HER2/TOP2A
locus, IHC scores were 0–1+, SISH ratios ranged from
1.0–1.5 and a TC% was 50–70 %. Patient ERPR+ 8 and
11 generated an equivocal result utilizing SNP 8 (2x
equivocal, 1x allelic instability) and 4 (3x equivocal),
respectively.
Discussion
We have shown that the presented SNP based real time
PCR assay is easy to perform and can be employed to re-
veal allelic instability of the HER2/TOP2A locus in
breast tissues. The assay yielded results that fell within
the normal range of data distribution in the control tis-
sues. SNP results were consistent (all informative SNPs
stable or instable) within most (42/44) tumor samples
and were indicative of abundant allelic imbalance in
HER2 amplified and TN tissues.
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observed by IHC, SNP results were found to be indicative
of HER2/TOP2A allelic instability. In 2 patients conflicting
results between informative SNPs were found. In one sam-
ple (patient HER2+ 1), SNP 1 (instable in 2/3 observations
and 1 equivocal) and SNP 10 results showed allelic instabil-
ity while no allelic instability was observed for SNP 8 and 9.
SISH analysis of this sample revealed no genomic amplifica-
tion of the HER2 locus. This possibly implies a false positive
IHC result or HER2 overexpession not related to gene amp-
lification, which has been reported in 3–8 % of breast tu-
mors [34–36]. However, the SNP assay did show the
presence of a genetic aberration of part of the locus under
investigation. Additionally, in patient HER2+ 6, allelic in-
stability was observed for 3 non-contiguous SNPs out of 6
informative SNPs. The other 3 non-contiguous SNPs
showed results indicative of a stable HER2/TOP2A locus.
These observations may be the result of a combination of
relatively small genetic aberrations each affecting part of
the locus.
In the TN group, 75 % of the tumor samples (12/16)
showed results indicative of allelic instability of the HER2/
TOP2A locus. This is in line with previous findings where
the complex genomic profiles, with numerous gains and
losses, of these tumors were classified as “sawtooth pat-
terns” [23–28]. Nineteen percent of the TN patients (3/16)
yielded results that were representative of a stable HER2/
TOP2A locus. In one sample (patient TN8) the only 2 in-
formative SNPs were found to be equivocal, making the
overall result with regard to the stability of the HER2/
TOP2A locus equivocal.
Within the ERPR+ group, 38 % of the tumor samples
(5/13) yielded results representative of allelic instability
of the HER2/TOP2A locus, whilst 62 % (8/13) did not.
Patient ERPR+ 7 showed discordant results in SNP 3,
which was therefore concluded to be equivocal. Al-
though the biological and/or technical rationale behind
this observation remains unclear, we believe that it is
justified to conclude that this sample harbors HER2/
TOP2A allelic instability due the data of the remaining 5
informative SNPs. Beside the HER2 normal tissue, pa-
tient ERPR+ 11 also harbored HER2 amplified tumor tis-
sue, which was most likely caused by the presence of a
second tumor or tumor heterogeneity. The tissue in-
cluded in this study, which had a stable HER2/TOP2A
locus, was not HER2 amplified and was ERPR positive.
This patient was therefore included in the ERPR+ group.
High chromosome instability, detected using FISH, in
breast tumors is of prognostic value with regard to clin-
ical outcome and may be useful in predicting response
to AC-based therapy [31], since topoisomerase is tar-
geted by AC. It is of particular interest whether these
observations are also true for the allelically imbalanced
groups found amongst the TN and the ERPR+ patientgroups using the presented SNP based assay. Although
the number of samples in our study is limited, the por-
tion of tumor samples that contain HER2/TOP2A allelic
instability in the TN and ERPR+ group (75 % and 38 %,
respectively) roughly corresponded to the AC-based
chemotherapy response rates found within these groups
(85 % and 47 %, respectively) [37]. A future study analyz-
ing patients with available 5 year clinical follow-up data
is needed to support this observation.
Overall, 8 out of 10 tissues where part of the tumor
cells harbored polysomy of chromosome 17, which was
detected by the chromosome 17 centromeric probe in-
cluded in the SISH assay, showed SNP results indicative
of allelic instability. The SNP observations however may
be the cumulative effect of several genetic aberrations
including the polysomia. Reflection of monosomy and
trisomy of chromosome 17 in the SNP results was less
evident. In all tumors where aneuploidy chromosome 17
was observed, heterogeneity was observed with regard to
chromosome 17 status as well.
SNP 3 cut-off values were adapted due to its large nor-
mal ratio distribution. Employing identically calculated
cut-off values for SNP 3 would lead to the unjustified
normal/equivocal calling of samples that clearly demon-
strate a deviant VIC/FAM delta Rn ratio based on the
generated scatterplot (data not shown).
In the histologically normal tissues, 99.5 % (207/208) of
the informative SNPs yielded results indicative of a stable
HER2/TOP2A locus. Since sample input of these tissues
was similar to those of the tumor tissues, PCR inhibition
and depletion of reagents, which may occur, do not seem
to be of major impact in allelic stability vs instability call-
ing. The same is true, after the correction of delta Rn
FAM values as described earlier, for variation in DNA
concentration. The single anomaly concerning SNP 11
that was found aberrant in a histologically normal sample
from the breast tumor group may be caused by a small de-
letion, point mutation(s) or a small recombination event
around the involved SNP. Although sequencing of this
SNP locus of this particular patient is of interest, it is be-
yond the scope of this study. Although the SNP test per-
formed well, some drawbacks may be encountered. When
analyzing a heterogeneous tumor tissue, unjustified (im)-
balance calling may occur. The resolution per SNP is rela-
tively low, which may lead to an inconclusive result when
(a large part of) the employed SNPs are homozygous and
therefore non-informative. However, this issue is easily
overcome by increasing the number of SNPs to be ana-
lysed. Determining the allelic instability of a sample with
the SNP assay, as described here, costs approximately
€50-€75 (US $55–85) per sample. These costs are com-
parable to those of FISH based allelic instability testing.
Additionally, the SNP test is well suited for the detection
of copy number variations, but is not able to distinguish
Huijsmans et al. Diagnostic Pathology  (2015) 10:56 Page 8 of 9between various underlying mechanisms (e.g. gains vs.
losses). SNP assays have a limited sensitivity, around 20 %
“mutant” DNA extracted from whole blood is detectable in
a “wildtype” background [32]. For FFPE tissues, this sensitiv-
ity might be even somewhat lower. Therefore, to prevent
false negativity with regard to allelic instability, the mini-
mum tumor cell percentage was set at 25 %. This implies
that allelic imbalance in minor tumor cell populations may
have stayed unnoticed. Unfortunately, further analysis of the
assays’ sensitivity was not possible due the lack of quantified
DNA affected by allelic instability. However, we do not ex-
pect DNA degradation to have a significant impact on the
assays’ sensitivity because of the small amplicons targeted
(up to 80 bp) in combination with the size of amplifiable
DNA fragments yielded by the employed DNA extraction
method [38].
To minimize the effect of pipetting inaccuracy and to
prevent pipetting errors, manual liquid handling was re-
duced to a minimum by performing all initial PCR setups
using a Hamilton StarLet robot. Any inaccuracies or er-
rors with regard to pipetting could negatively influence
the determination of the natural ratio distribution of the
histologically normal tissues and ultimately the allelic sta-
bility vs. instability calling.
Conclusions
In summary, the presented SNP methodology is easy to per-
form when compared to other copy number variation detec-
tion techniques such as array based systems targeting SNPs
and Comparative Genomic Hybridization and corresponds
well to positive SISH results. The real time PCR based SNP
test may have an added value in the TN as well as the
ERPR+ patient group. Within these groups, 75 % of the TN
and 38 % of the ERPR+ tumors showed allelic instability
with the SNP based assay. To determine such a possible
added value of the presented SNP test a large-scale study
should be performed. Ample size TN and ERPR+ patient
groups with 5 year clinical follow-up data should be in-
cluded to assess whether the determination of allelic in-
stability of the HER2/TOP2A locus as a marker has clinical
relevance and is of any significance for therapeutic decision
making.
Additional files
Additional file 1: Table S1. Patient data and SNP test results from the
control group. Patient data and SNP results. The top right represents the
HER2/TOP2A locus and the schematic positions of the employed SNP
markers. The arrows indicate the location of the HER2 and TOP2A genes. The
boxes represent all informative SNPs that were considered not affected
(green)/affected (red) by allelic instability or equivocal (grey). Homozygous
SNPs are not informative, and are therefore shown as a horizontal line.
Additional file 2: Table S2. Patient data, tumor characteristics and IHC,
SISH and SNP test results from breast tumor group. Patient data, tumor
characteristics and IHC, SISH and SNP test results. L and B represent the use oflymph node or breast histologically normal tissue. IHC= immunohistochemistry,
SISH = silver in situ hybridization, HER2+=HER2 overexpression observed based
on IHC, TN= triple negative, ERPR+= estrogen receptor and progesterone
receptor positive. Chr17 status = chromosome 17 status with M (monosomy),
D (disomy), T (trisomy) and P (polysomy) as possible outcomes supplemented
with the number of chromosomes 17 observed per nucleus.
Pred. = predominantly and TC% = tumor cell percentage. Failed = SISH
repeatedly failed. The top right represents the HER2/TOP2A locus and
the schematic positions of the employed SNP markers. The arrows
indicate the location of the HER2 and TOP2A genes. The boxes represent
all informative SNPs that were considered not affected (green)/affected
(red) by allelic instability or equivocal (grey). Homozygous SNPs are not
informative, and are therefore shown as a horizontal line.Competing interests
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